Clinical outcome in patients receiving systemic therapy for metastatic sarcomatoid renal cell carcinoma: A retrospective analysis☆
Sumanta K. Pal(City of Hope), Clayton Lau(City of Hope), Robert A. Figlin(Palmetto Hematology Oncology), Joanne I. Hsu(Brigham and Women's Hospital), Courtney Carmichael(City of Hope), Xueli Liu(City of Hope), Junmi Saikia(City of Hope), Przemyslaw Twardowski(Saint John's Health Center), Jeremy O. Jones(Idaho National Laboratory)
Cited by 21
Related Papers
Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial
|Nature Medicine|2022|453
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy
|Cell stem cell|2018|423
Association of Patient Sex With Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers
|JAMA Oncology|2019|302
Highly Efficient Genome Editing of Murine and Human Hematopoietic Progenitor Cells by CRISPR/Cas9
|Cell Reports|2016|283
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|184